Shares of Iovance Biotherapeutics, Inc. (IOVA) soared 13.82% in pre-market trading on Thursday, following the release of the company's impressive third-quarter 2025 financial results and business achievements. The biotechnology firm reported significant revenue growth and improved operational efficiency, sparking investor optimism.

Iovance announced a 13% increase in total product revenue compared to the previous quarter, reaching approximately $68 million. This growth was primarily driven by U.S. Amtagvi sales of around $58 million and global Proleukin revenue of about $10 million. Notably, the company's gross margin improved to 43%, which management attributed to enhanced execution and operational efficiency.

The strong financial performance was complemented by positive developments in Iovance's business operations. The company reported growing demand for Amtagvi, its flagship product, and ongoing integration of community treatment centers. Additionally, Iovance highlighted continued progress in its development programs for solid tumor cancers, signaling potential for future growth and expansion in the oncology market. These factors combined appear to have boosted investor confidence, leading to the significant pre-market stock surge.